Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Nuno Loureiro, MIT physicist, fatally shot at home; police investigate - 2Figure out How to Get a good deal on Your Rooftop Substitution Venture
- 3New law puts familiar drinks, creams and gummies in legal limbo
- 4Russia accidentally destroys its only way of sending astronauts to space
- 5Pick Your Favored kind of sandwich
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- California is completely free of drought for the first time in 25 years
- Former GLP-1 users regain lost weight after about 18 months, study says
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Flu cases spiking this holiday season, CDC data shows
